

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM346752

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
AngioScore Inc.		06/26/2015	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Wells Fargo Bank, National Association		
Street Address:	1740 Broadway, MAC C7300-122		
City:	Denver		
State/Country:	COLORADO		
Postal Code:	80274		
Entity Type:	National Association: UNITED STATES		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	2931808	ANGIOSCORE	
Registration Number:	2920010	ANGIOSCULPT	
Serial Number:	86115902	HYDROCROSS	
CORRESPONDENCE DATA			
Fax Number:	4352143811		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	435-214-3807		
Email:	mjones@markuswilliams.com		
Correspondent Name:	Melinda Jones		
Address Line 1:	2750 Rasmussen Road, Suite H-104		
Address Line 4:	Park City, UTAH 84098		
ATTORNEY DOCKET NUMBER:	10918.544		
NAME OF SUBMITTER:	Melinda Jones		
SIGNATURE:	/mej/		
DATE SIGNED:	07/02/2015		
Total Attachments: 11			
source=Patent and Trademark Security Agreement - AngioScore Inc#page1.tif			
source=Patent and Trademark Security Agreement - AngioScore Inc#page2.tif			
source=Patent and Trademark Security Agreement - AngioScore Inc#page3.tif			

CH \$90.00 2931808

source=Patent and Trademark Security Agreement - AngioScore Inc#page4.tif
source=Patent and Trademark Security Agreement - AngioScore Inc#page5.tif
source=Patent and Trademark Security Agreement - AngioScore Inc#page6.tif
source=Patent and Trademark Security Agreement - AngioScore Inc#page7.tif
source=Patent and Trademark Security Agreement - AngioScore Inc#page8.tif
source=Patent and Trademark Security Agreement - AngioScore Inc#page9.tif
source=Patent and Trademark Security Agreement - AngioScore Inc#page10.tif
source=Patent and Trademark Security Agreement - AngioScore Inc#page11.tif

PATENT AND TRADEMARK SECURITY AGREEMENT

This Patent and Trademark Security Agreement (this "Agreement"), dated as of June 26, 2015, is made by and between AngioScore Inc., a Delaware corporation having a business location at the address set forth below next to its signature ("Debtor"), and Wells Fargo Bank, National Association ("Wells Fargo"), having a business location at the address set forth below next to its signature.

Recitals

The Spectranetics Corporation, a Delaware corporation ("Company"), and Wells Fargo are parties to a Credit and Security Agreement (as amended, supplemented or restated from time to time, the "Credit Agreement") dated as of February 25, 2011, setting forth the terms on which Wells Fargo may now or hereafter extend credit to or for the account of Company.

Debtor is a subsidiary of Company, and Debtor and Wells Fargo are parties to a Guarantor Security Agreement (as amended, supplemented or restated from time to time, the "Guarantor Security Agreement") dated as of June 26, 2015.

As a condition to extending credit to or for the account of Company, Wells Fargo has required the execution and delivery of this Agreement by Debtor.

ACCORDINGLY, in consideration of the mutual covenants contained in the Loan Documents and herein, the parties hereby agree as follows:

1. Definitions. All terms defined in the Recitals hereto or in the Credit Agreement that are not otherwise defined herein shall have the meanings given to them in the Credit Agreement. In addition, the following terms have the meanings set forth below:

"Patents" means all of Debtor's right, title and interest in and to U.S. patents or applications for U.S. patents, together with all fees or royalties with respect to each, and including without limitation the right to sue for past infringement and damages therefor, and licenses thereunder, all as presently existing or hereafter arising or acquired, including without limitation the patents listed on Exhibit A.

"Security Interest" has the meaning given in Section 2.

"Trademarks" means all of Debtor's right, title and interest in and to:
(i) trademarks, service marks, collective membership marks, U.S. registrations and applications for U.S. registration for each, and the respective goodwill associated with each, (ii) licenses, fees or royalties with respect to each, (iii) the right to sue for past, present and future infringement, dilution and damages therefor, and (iv) licenses thereunder, all as presently existing or hereafter arising or acquired, including, without limitation, the marks listed on Exhibit B.

2. Security Interest. Debtor hereby irrevocably pledges and assigns to, and grants Wells Fargo a security interest (the "Security Interest") with power of sale to the extent permitted by law, in the Patents and in the Trademarks to secure payment of the Indebtedness.

As set forth in the Credit Agreement, the Security Interest is coupled with a security interest in substantially all of the personal property of Debtor. This Agreement grants only the Security Interest herein described, is not intended to and does not affect any present transfer of title of any trademark registration or application and makes no assignment and grants no right to assign or perform any other action with respect to any intent to use trademark application, unless such action is permitted under 15 U.S.C. § 1060.

3. Representations, Warranties and Agreements. Debtor represents, warrants and agrees as follows:

(a) **Existence; Authority.** Debtor is a corporation duly incorporated, validly existing and in good standing under the laws of its state of incorporation and this Agreement has been duly and validly authorized by all necessary corporate action on the part of Debtor.

(b) **Patents.** Exhibit A accurately lists all Patents owned by Debtor as of the date hereof, or to which Debtor has a right as of the date hereof to have assigned to it, and accurately reflects the existence of applications for Patents owned by Debtor as of the date hereof. If after the date hereof, Debtor owns, controls or has a right to have assigned to it any Patents not listed on Exhibit A, or if Exhibit A ceases to accurately reflect the existence and status of applications and letters patent pertaining to the Patents, then Debtor shall within 60 days provide written notice to Wells Fargo with a replacement Exhibit A, which upon acceptance by Wells Fargo shall become part of this Agreement.

(c) **Trademarks.** Exhibit B accurately lists all Trademarks owned by Debtor as of the date hereof and accurately reflects the existence of all applications for Trademark registrations as of the date hereof; provided, however, that Exhibit B need not list common law marks (i.e., Trademarks for which there are no applications or registrations) which are not material to Debtor's or any Affiliate's business(es). If after the date hereof, Debtor owns or controls any Trademarks not listed on Exhibit B (other than common law marks which are not material to Debtor's or any Affiliate's business(es)), or if Exhibit B ceases to accurately reflect the existence and status of applications and registrations pertaining to the Trademarks, then Debtor shall promptly provide written notice to Wells Fargo with a replacement Exhibit B, which upon acceptance by Wells Fargo shall become part of this Agreement.

(d) **Affiliates.** As of the date hereof, and except as indicated on Exhibit A, no Affiliate owns, controls, or has a right to have assigned to it any items that would, if such item were owned by Debtor, constitute Patents or Trademarks. If after the date hereof any Affiliate owns, controls, or has a right to have assigned to it any such items, then Debtor shall promptly either: (i) cause such Affiliate to assign all of its rights in such item(s) to Debtor; or (ii) notify Wells Fargo of such item(s) and cause such Affiliate to execute and deliver to Wells Fargo a patent and trademark security agreement substantially in the form of this Agreement.

(e) **Title.** Debtor has absolute title to each Patent and each Trademark listed on Exhibits A and B, free and clear of all Liens except Permitted Liens. Debtor (i) will

have, at the time Debtor acquires any rights in Patents or Trademarks hereafter arising, absolute title to each such Patent or Trademark free and clear of all Liens except Permitted Liens, and (ii) will keep all Patents and Trademarks free and clear of all Liens except Permitted Liens.

(f) **No Sale.** Except as permitted in the Credit Agreement, Debtor will not assign, transfer, encumber or otherwise dispose of the Patents or Trademarks, or any interest therein, without Wells Fargo's prior written consent.

(g) **Defense.** Debtor will at its own expense and using commercially reasonable efforts, protect and defend the Patents and Trademarks against all claims or demands of all Persons other than those holding Permitted Liens.

(h) **Maintenance.** Debtor will at its own expense maintain the Patents and the Trademarks to the extent reasonably advisable in its business including, but not limited to, filing all applications to obtain letters patent or trademark registrations and all affidavits, maintenance fees, annuities, and renewals possible with respect to letters patent, trademark registrations and applications therefor. Debtor covenants that it will not abandon nor fail to pay any maintenance fee or annuity due and payable on any Patent or Trademark, nor fail to file any required affidavit or renewal in support thereof, without first providing Wells Fargo: (i) sufficient written notice, of at least 30 days, to allow Wells Fargo to timely pay any such maintenance fees or annuities which may become due on any Patents or Trademarks, or to file any affidavit or renewal with respect thereto, and (ii) a separate written power of attorney or other authorization to pay such maintenance fees or annuities, or to file such affidavit or renewal, should such be necessary or desirable.

(i) **Wells Fargo's Right to Take Action.** If Debtor fails to perform or observe any of its covenants or agreements set forth in this Section 3, and if such failure continues for a period of ten (10) calendar days after Wells Fargo gives Debtor written notice thereof (or, in the case of the agreements contained in subsection (h), immediately upon the occurrence of such failure, without notice or lapse of time), or if Debtor notifies Wells Fargo that it intends to abandon a Patent or Trademark other than a Patent or Trademark that Debtor has reasonably determined is no longer useful in its business, Wells Fargo may (but need not) perform or observe such covenant or agreement or take steps to prevent such intended abandonment on behalf and in the name, place and stead of Debtor (or, at Wells Fargo's option, in Wells Fargo's own name) and may (but need not) take any and all other actions which Wells Fargo may reasonably deem necessary to cure or correct such failure or prevent such intended abandonment.

(j) **Costs and Expenses.** Except to the extent that the effect of such payment would be to render any loan or forbearance of money usurious or otherwise illegal under any applicable law, Debtor shall pay Wells Fargo on demand the amount of all moneys expended and all costs and expenses (including reasonable attorneys' fees and disbursements) incurred by Wells Fargo in connection with or as a result of Wells Fargo's taking action under subsection (i) or exercising its rights under Section 6,

together with interest thereon from the date expended or incurred by Wells Fargo at the Default Rate.

(k) ***Power of Attorney.*** To facilitate Wells Fargo's taking action under subsection (i) and exercising its rights under Section 6, Debtor hereby irrevocably appoints (which appointment is coupled with an interest) Wells Fargo, or its delegate, as the attorney-in-fact of Debtor with the right (but not the duty) from time to time to create, prepare, complete, execute, deliver, endorse or file, in the name and on behalf of Debtor, any and all instruments, documents, applications, financing statements, and other agreements and writings required to be obtained, executed, delivered or endorsed by Debtor under this Section 3, or, necessary for Wells Fargo, after an Event of Default, to enforce or use the Patents or Trademarks or to grant or issue any exclusive or non-exclusive license under the Patents or Trademarks to any third party, or to sell, assign, transfer, pledge, encumber or otherwise transfer title in or dispose of the Patents or Trademarks to any third party. Debtor hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof. The power of attorney granted herein shall terminate upon the termination of the Credit Agreement as provided therein and the payment and performance of all Indebtedness.

4. **Debtor's Use of the Patents and Trademarks.** Debtor shall be permitted to control and manage the Patents and Trademarks, including the right to exclude others from making, using or selling items covered by the Patents and Trademarks and any licenses thereunder, in the same manner and with the same effect as if this Agreement had not been entered into, so long as no Event of Default occurs and remains uncured.

5. **Events of Default.** Each of the following occurrences shall constitute an event of default under this Agreement (herein called "Event of Default"): (a) an Event of Default, as defined in the Credit Agreement, shall occur; or (b) Debtor shall fail promptly to observe or perform any covenant or agreement herein binding on it; or (c) any of the representations or warranties contained in Section 3 shall prove to have been incorrect in any material respect when made.

6. **Remedies.** Upon the occurrence of an Event of Default and at any time thereafter, Wells Fargo may, at its option, take any or all of the following actions:

(a) Wells Fargo may exercise any or all remedies available under the Credit Agreement.

(b) Wells Fargo may sell, assign, transfer, pledge, encumber or otherwise dispose of the Patents and Trademarks.

(c) Wells Fargo may enforce the Patents and Trademarks and any licenses thereunder, and if Wells Fargo shall commence any suit for such enforcement, Debtor shall, at the request of Wells Fargo, do any and all lawful acts and execute any and all proper documents required by Wells Fargo in aid of such enforcement.

7. **Miscellaneous.** This Agreement can be waived, modified, amended, terminated or discharged, and the Security Interest can be released, only explicitly in a writing signed by

Wells Fargo. A waiver signed by Wells Fargo shall be effective only in the specific instance and for the specific purpose given. Mere delay or failure to act shall not preclude the exercise or enforcement of any of Wells Fargo's rights or remedies. All rights and remedies of Wells Fargo shall be cumulative and may be exercised singularly or concurrently, at Wells Fargo's option, and the exercise or enforcement of any one such right or remedy shall neither be a condition to nor bar the exercise or enforcement of any other. All notices to be given to Debtor under this Agreement shall be given in the manner and with the effect provided in the Credit Agreement. Wells Fargo shall not be obligated to preserve any rights Debtor may have against prior parties, to realize on the Patents and Trademarks at all or in any particular manner or order, or to apply any cash proceeds of Patents and Trademarks in any particular order of application. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one and the same instrument. Delivery of an executed counterpart of this Agreement by telefacsimile or other electronic means shall be equally as effective as delivery of an original executed counterpart of this Agreement. Any party delivering an executed counterpart of this Agreement by telefacsimile or other electronic means also shall deliver an original executed counterpart of this Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Agreement. This Agreement shall be binding upon and inure to the benefit of Debtor and Wells Fargo and their respective participants, successors and assigns and shall take effect when signed by Debtor and delivered to Wells Fargo, and Debtor waives notice of Wells Fargo's acceptance hereof. Wells Fargo may execute this Agreement if appropriate for the purpose of filing, but the failure of Wells Fargo to execute this Agreement shall not affect or impair the validity or effectiveness of this Agreement. A carbon, photographic or other reproduction of this Agreement or of any financing statement signed by Debtor shall have the same force and effect as the original for all purposes of a financing statement. This Agreement shall be governed by the internal law of Colorado without regard to conflicts of law provisions. If any provision or application of this Agreement is held unlawful or unenforceable in any respect, such illegality or unenforceability shall not affect other provisions or applications which can be given effect and this Agreement shall be construed as if the unlawful or unenforceable provision or application had never been contained herein or prescribed hereby. All representations and warranties contained in this Agreement shall survive the execution, delivery and performance of this Agreement and the creation and payment of the Indebtedness.

THE PARTIES WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING BASED ON OR PERTAINING TO THIS AGREEMENT.

[The remainder of this page intentionally left blank.]

IN WITNESS WHEREOF, the parties have executed this Patent and Trademark Security Agreement as of the date written above.


AngioScore Inc.
c/o The Spectranetics Corporation
9965 Federal Drive
Colorado Springs, Colorado 80921

ANGIOSCORE INC.

By: _____
Name: Guy A. Childs
Its: Chief Financial Officer

Wells Fargo Bank, National Association
MAC C7300-122
1740 Broadway
Denver, Colorado 80274

WELLS FARGO BANK, NATIONAL ASSOCIATION

By: 
Name: Dustin Jacobson
Its: Authorized Signatory


STATE OF COLORADO)
)
COUNTY OF EL PASO)

The foregoing instrument was acknowledged before me this ___ day of June, 2015, by Guy A. Childs, the Chief Financial Officer of AngioScore Inc., a Delaware corporation, on behalf of the corporation.

Notary Public

STATE OF COLORADO)
)
CITY AND COUNTY OF DENVER)

The foregoing instrument was acknowledged before me this 25 day of June, 2015, by Dustin Jacobson, an Authorized Signatory of Wells Fargo Bank, National Association, on behalf of the national association.



Notary Public

**ANN CORONADO
NOTARY PUBLIC
STATE OF COLORADO
NOTARY ID 20034024650
MY COMMISSION EXPIRES JULY 25, 2019**

EXHIBIT A**UNITED STATES ISSUED PATENTS**

Patent Description	Registration Number	Registration Date
APPARATUS AND METHODS FOR TREATING HARDENED VASCULAR LESIONS	8,454,636	6/4/2013
APPARATUS AND METHODS FOR TREATING HARDENED VASCULAR LESIONS	8,080,026	12/20/2011
APPARATUS AND METHODS FOR TREATING HARDENED VASCULAR LESIONS	7,686,824	3/30/2010
APPARATUS AND METHODS FOR TREATING HARDENED VASCULAR LESIONS	7,955,350	6/7/2011
APPARATUS AND METHODS FOR TREATING HARDENED VASCULAR LESIONS	8,721,667	5/13/2014
COATING FORMULATIONS FOR SCORING OR CUTTING BALLOON CATHETERS	9,011,896	4/21/2015
Methods and Systems for Delivering Substances Into Luminal Walls	8,864,743	10/21/2014
METHOD AND SYSTEM FOR TREATING VALVE STENOSIS	8,632,559	1/21/2014
BALLOON CATHETER WITH NON-DEPLOYABLE STENT	7,931,663	4/26/2011
FACILITATED BALLOON CATHETER EXCHANGE	7,022,104	4/4/2006
FACILITATED BALLOON CATHETER EXCHANGE	7,513,886	4/7/2009
BALLOON CATHETER WITH NON-	7,691,119	4/6/2010

DEPLOYABLE STENT		
------------------	--	--

UNITED STATES PATENT APPLICATIONS AND ADDITIONS

Patent Application	Application/Serial Number	Application/Filing Date
BALLOON CATHETER WITH NON-DEPLOYABLE STENT HAVING IMPROVED STABILITY	14/048,955	10/8/2013
APPARATUS AND METHODS FOR TREATING HARDENED VASCULAR LESIONS	14/275,264	5/12/2014
COATING FORMULATIONS FOR SCORING OR CUTTING BALLOON CATHETERS	13/628,627	9/27/2012
COATING FORMULATIONS FOR SCORING OR CUTTING BALLOON CATHETERS	13/975,209	8/23/2013
COATING FORMULATIONS FOR SCORING OR CUTTING BALLOON CATHETERS	13/975,220	8/23/2013
COATING FORMULATIONS FOR SCORING OR CUTTING BALLOON CATHETERS	13/975,228	8/23/2013
METHODS AND SYSTEMS FOR DELIVERING SUBSTANCES INTO LUMINAL WALLS	11/411,635	4/26/2006
METHODS AND SYSTEMS FOR DELIVERING SUBSTANCES INTO LUMINAL WALLS	13/842,080	3/15/2013
METHOD AND SYSTEM FOR TREATING VALVE STENOSIS	13/894,613	5/15/2013

Patent Application	Application/Serial Number	Application/Filing Date
METHOD AND SYSTEM FOR TREATING VALVE STENOSIS	14/010,754	8/27/2013
BALLOON CATHETER WITH NON-DEPLOYABLE STENT	12/694,163	1/26/2010
BALLOON CATHETER WITH NON-DEPLOYABLE STENT	13/022,489	2/7/2011
BALLOON CATHETER WITH NON-DEPLOYABLE STENT	13/489,250	6/5/2011

EXHIBIT B

**UNITED STATES ISSUED TRADEMARKS, SERVICE MARKS
AND COLLECTIVE MEMBERSHIP MARKS**

REGISTRATIONS

Trademark	Registration Number	Registration Date
ANGIOSCORE	2,931,808	March 8, 2005
ANGIOSCULPT	2,920,010	January 18, 2005

APPLICATIONS

Trademark Application	Application/Serial Number	Application Date
HYDROCROSS	86/115,902	November 11, 2013

COLLECTIVE MEMBERSHIP MARKS

NONE

UNREGISTERED MARKS

NONE